Alzheimer’s disease is a progressive neurodegenerative disease and the most common cause of dementia. To discriminate Alzheimer’s disease dementia cases from cognitively normal controls, the levels of beta-amyloid 1-42 (Aβ42) in the cerebrospinal fluid have been shown to have diagnostic significance. The concentration of Aβ42in CSF drops significantly 5-10 years prior to the establishment of cognitive impairment symptoms so it can be used as a biomarker at the earliest stages of the disease progression.

Aβ42 can be used for diagnostics of Alzheimer’s disease in both the prodromal and dementia stage of the disease, and it is included in the diagnostic research criteria for Alzheimer’s disease.

We provide three in vitro produced monoclonal antibodies that are specific to human beta-amyloid 1-42. Correlation studies show good correlation between the prototype sandwich immunoassays and a commercially available test (INNOTEST BETA-AMYLOID (1-42) from Fujirebio, see Figure).